Publications by authors named "David M Gershenson"

100Publications

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS or KRAS mutations.

Sci Rep 2020 11 26;10(1):20678. Epub 2020 Nov 26.

Department of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article and Find Full Text PDF
November 2020

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum.

Gynecol Oncol Rep 2020 Nov 2;34:100670. Epub 2020 Nov 2.

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA.

View Article and Find Full Text PDF
November 2020

The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy.

Cancers (Basel) 2020 Oct 19;12(10). Epub 2020 Oct 19.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF
October 2020

Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Int J Gynecol Cancer 2020 Nov 5;30(11):1733-1737. Epub 2020 Oct 5.

Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article and Find Full Text PDF
November 2020

Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors.

Gynecol Oncol 2020 Dec 2;159(3):601-603. Epub 2020 Oct 2.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article and Find Full Text PDF
December 2020

MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.

J Clin Oncol 2020 Nov 8;38(32):3731-3734. Epub 2020 Sep 8.

Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.

View Article and Find Full Text PDF
November 2020

The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.

Gynecol Oncol 2020 Sep 22;158(3):653-658. Epub 2020 Jul 22.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.

View Article and Find Full Text PDF
September 2020

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review.

Cancers (Basel) 2020 May 29;12(6). Epub 2020 May 29.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77033, USA.

View Article and Find Full Text PDF
May 2020

Significance of lymph node ratio on survival of women with borderline ovarian tumors.

Arch Gynecol Obstet 2020 05 17;301(5):1289-1298. Epub 2020 Apr 17.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD 520, Los Angeles, CA, 90033, USA.

View Article and Find Full Text PDF
May 2020

Rare Gynecologic Tumors: Coming of Age.

Gynecol Oncol 2020 04;157(1):1-2

Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire (GINECO), Lyon, France.

View Article and Find Full Text PDF
April 2020

Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.

Gynecol Oncol 2020 04 15;157(1):21-28. Epub 2020 Jan 15.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
April 2020

Evolving population-based statistics for rare epithelial ovarian cancers.

Gynecol Oncol 2020 04 15;157(1):3-11. Epub 2020 Jan 15.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.

View Article and Find Full Text PDF
April 2020

Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.

Obstet Gynecol 2019 12;134(6):1253-1259

Departments of Gynecologic Oncology and Reproductive Medicine, Biostatistics, and Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas; the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Olive View/UCLA Medical Center, Los Angeles, California; and the Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, Maryland.

View Article and Find Full Text PDF
December 2019

Management of rare epithelial ovarian cancers.

Clin Adv Hematol Oncol 2019 Aug;17(8):444-446

University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
August 2019

Management of Rare Ovarian Cancer Histologies.

J Clin Oncol 2019 09 12;37(27):2406-2415. Epub 2019 Aug 12.

Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire (GINECO), Lyon, France.

View Article and Find Full Text PDF
September 2019

Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

Gynecol Oncol 2019 05 20;153(2):230-237. Epub 2019 Feb 20.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
May 2019

Low grade serous ovarian carcinoma: identifying variations in practice patterns.

Int J Gynecol Cancer 2019 01;29(1):174-180

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA

View Article and Find Full Text PDF
January 2019

Treatment of Rare Epithelial Ovarian Tumors.

Hematol Oncol Clin North Am 2018 12;32(6):1011-1024

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler, Unit 1362, Houston, TX 77030, USA.

View Article and Find Full Text PDF
December 2018

Complete Resection Is Essential in the Surgical Treatment of Gestational Trophoblastic Neoplasia.

Int J Gynecol Cancer 2018 10;28(8):1453-1460

Division of Gynecologic Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article and Find Full Text PDF
October 2018

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Gynecol Oncol 2018 08 18;150(2):247-252. Epub 2018 Jun 18.

Department of GYN/ONC, Unit 1362, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230, United States. Electronic address:

View Article and Find Full Text PDF
August 2018

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

Gynecol Oncol 2018 07 5;150(1):9-13. Epub 2018 May 5.

Department of Gynecologic Oncology & Reproductive Medicine, Unit 1362, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article and Find Full Text PDF
July 2018

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Gynecol Oncol 2018 06 24;149(3):605-611. Epub 2018 Apr 24.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, United States. Electronic address:

View Article and Find Full Text PDF
June 2018

Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type.

J Minim Invasive Gynecol 2019 01 19;26(1):87-93. Epub 2018 Apr 19.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article and Find Full Text PDF
January 2019

Trends of low-grade serous ovarian carcinoma in the United States.

J Gynecol Oncol 2018 01;29(1):e15

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
January 2018

DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.

Gynecol Oncol 2017 12 14;147(3):521-527. Epub 2017 Oct 14.

International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, MN, United States; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

View Article and Find Full Text PDF
December 2017

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Gynecol Oncol 2017 10 24;147(1):3-10. Epub 2017 Aug 24.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article and Find Full Text PDF
October 2017

Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?

Gynecol Oncol 2017 07 2;146(1):74-80. Epub 2017 May 2.

Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. Electronic address:

View Article and Find Full Text PDF
July 2017

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

J Clin Oncol 2017 Apr 21;35(10):1103-1111. Epub 2017 Feb 21.

All authors: University of Texas MD Anderson Cancer Center, Houston, TX.

View Article and Find Full Text PDF
April 2017

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.

Oncotarget 2017 Mar;8(10):16951-16963

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
March 2017

Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.

Gynecol Oncol 2017 04 27;145(1):37-40. Epub 2017 Jan 27.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article and Find Full Text PDF
April 2017

Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.

Gynecol Oncol 2017 03 26;144(3):496-502. Epub 2017 Jan 26.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
March 2017

Ovarian Sex Cord-Stromal Tumors.

J Oncol Pract 2016 10;12(10):940-946

Children's Hospitals and Clinics of Minnesota, Minneapolis, MN; Massachusetts General Hospital, Harvard Medical School; Dana-Farber Cancer Center/Children's Cancer Care, Boston, MA; Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Washington University Medical Center, St Louis, MO; Children's National Medical Center and Center for Genetic Medicine Research, Children's Research Institute, Washington, DC; and Clinic of Pediatrics, Dortmund, Germany.

View Article and Find Full Text PDF
October 2016

Management of borderline ovarian tumours.

Best Pract Res Clin Obstet Gynaecol 2017 May 3;41:49-59. Epub 2016 Oct 3.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Unit 1362, 1155 Pressler Drive, Houston, TX 77030, USA. Electronic address:

View Article and Find Full Text PDF
May 2017

Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.

Gynecol Oncol 2016 Nov 25;143(2):428-432. Epub 2016 Aug 25.

Dana-Farber/Boston Children's Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article and Find Full Text PDF
November 2016

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.

Oncotarget 2016 Aug;7(35):56933-56943

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
August 2016

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.

Br J Cancer 2015 Nov 20;113(9):1254-8. Epub 2015 Oct 20.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF
November 2015

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.

Gynecol Oncol Rep 2015 Aug 11;13:36-9. Epub 2015 Jun 11.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD-Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
August 2015

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

J Clin Oncol 2015 Dec 31;33(34):4099-105. Epub 2015 Aug 31.

Rachel N. Grisham, Brooke E. Sylvester, Helen Won, Deborah DeLair, Zhan Yao, Ronglai Shen, Fanny Dao, Faina Bogomolniy, Vicky Makker, Evis Sala, Tara E. Soumerai, David M. Hyman, Douglas A. Levine, Neal Rosen, Michael F. Berger, David R. Spriggs, Carol A. Aghajanian, David B. Solit, and Gopa Iyer, Memorial Sloan Kettering Cancer Center; Rachel N. Grisham, Gregory McDermott, Vicky Makker, David M. Hyman, Neal Rosen, Michael F. Berger, David R. Spriggs, Carol A. Aghajanian, David B. Solit, and Gopa Iyer, Weill Cornell Medical College; Ricardo Ramirez, Graduate School of Medical Sciences; Nicholas D. Socci and Agnes Viale, Michael F. Berger, and David B. Solit, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, New York, NY; David M. Gershenson, University of Texas MD Anderson Cancer Center, Houston, TX; and John Farley, St Joseph's Hospital and Medical Center, Phoenix, AZ.

View Article and Find Full Text PDF
December 2015

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

J Clin Oncol 2015 Sep 24;33(27):3018-28. Epub 2015 Aug 24.

Thomas A. Olson, Emory University, Atlanta, GA; Matthew J. Murray and James C. Nicholson, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, United Kingdom; Carlos Rodriguez-Galindo and A. Lindsay Frazier, Boston Children's Hospital, Boston; Carlos Rodriguez-Galindo, A. Lindsay Frazier, and Christopher Sweeney, Dana-Farber Cancer Institute, Boston, MA; Deborah F. Billmore, Riley Hospital for Sick Children, Indianapolis, IN; Mark D. Krailo and Ha M. Dang, University of Southern California, Los Angeles, CA; James F. Amatruda, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas; David M. Gershenson, University of Texas MD Anderson Cancer Center, Houston, TX; Claire M. Thornton, Royal Victoria Hospital, Belfast, United Kingdom; G. Suren Arul, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom; Sara J. Stoneham, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Farzana Pashankar, Yale University School of Medicine, New Haven, CT; Daniel Stark, University of Leeds, Leeds, United Kingdom; Furqan Shaikh, The Hospital for Sick Children, Toronto; Allan Covens, University of Toronto, Toronto, Ontario, Canada; Jean Hurteau, University of Chicago Pritzker School of Medicine, Chicago, IL; Sally P. Stenning, Medical Research Council, London, United Kingdom; Darren R. Feldman, Memorial Sloan Kettering Cancer Center, New York, NY; Peter S. Grimison, Sydney Cancer Center, Sydney, New South Wales, Australia; Robert A. Huddart, Institute of Cancer Research and Royal Marsden Hospital, Surrey, United Kingdom; Thomas Powles, Barts Cancer Institute, London, United Kingdom; Luiz Fernando Lopes, Barretos Pediatric Cancer Center, São Paulo, Brazil; Simone dos Santos Agular, Centro Infantil Boldrini, Campinas, Brazil; Girish Chinnaswamy, Tata Memorial Hospital, Mumbai, India; Sahar Khaleel and Sherif Abouelnaga, Children's Cancer Hospital, Cairo, Egypt; and Jul

View Article and Find Full Text PDF
September 2015

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.

PLoS One 2015 6;10(8):e0135101. Epub 2015 Aug 6.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Cancer Biology Program, The University of Texas at Houston Graduate School of Biomedical Sciences, Houston, Texas, United States of America.

View Article and Find Full Text PDF
May 2016

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

J Clin Oncol 2015 Mar 26;33(8):930-6. Epub 2015 Jan 26.

Brian M. Slomovitz, Yunyun Jiang, Melinda S. Yates, Pamela T. Soliman, Taren Johnston, Charles Levenback, Qian Zhang, Kari Ring, Mark F. Munsell, David M. Gershenson, Karen H. Lu, and Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian M. Slomovitz and Maureen Nowakowski, Morristown Medical Center, Morristown, NJ; and Brian M. Slomovitz, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL.

View Article and Find Full Text PDF
March 2015

Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

Gynecol Oncol 2015 Feb 3;136(2):373-83. Epub 2014 Dec 3.

The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, MD, USA. Electronic address:

View Article and Find Full Text PDF
February 2015

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.

Gynecol Oncol 2015 Jan 8;136(1):25-9. Epub 2014 Nov 8.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article and Find Full Text PDF
January 2015

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

J Pathol 2013 Dec;231(4):449-56

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article and Find Full Text PDF
December 2013

Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.

Gynecol Oncol 2014 Apr 15;133(1):100-4. Epub 2014 Feb 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Electronic address:

View Article and Find Full Text PDF
April 2014

Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.

Cancer 2014 Feb 24;120(3):344-51. Epub 2013 Oct 24.

Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
February 2014

Ovarian cancer, version 2.2013.

J Natl Compr Canc Netw 2013 Oct;11(10):1199-209

From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.

View Article and Find Full Text PDF
October 2013

Survival in women with grade 1 serous ovarian carcinoma.

Obstet Gynecol 2013 Aug;122(2 Pt 1):225-232

Johns Hopkins Medical Institutions, Baltimore, Maryland; the Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York; the University of California San Francisco, Comprehensive Cancer Center, San Francisco, and the University of California, Irvine Medical Center, Orange, California; the University of Arizona, Tucson, Arizona; and the University of Texas, MD Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
August 2013

Poor survival with wild-type TP53 ovarian cancer?

Gynecol Oncol 2013 Sep 22;130(3):565-9. Epub 2013 Jun 22.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF
September 2013

The life and times of low-grade serous carcinoma of the ovary.

Am Soc Clin Oncol Educ Book 2013

From the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article and Find Full Text PDF
November 2015

Low-grade serous carcinoma: new concepts and emerging therapies.

Gynecol Oncol 2013 Sep 23;130(3):660-6. Epub 2013 May 23.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA.

View Article and Find Full Text PDF
September 2013

PAX2 Expression in Ovarian Cancer.

Int J Mol Sci 2013 Mar 15;14(3):6090-105. Epub 2013 Mar 15.

Department of Gynecologic Oncology and Reproductive Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF
March 2013

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

Lancet Oncol 2013 Feb 21;14(2):134-40. Epub 2012 Dec 21.

Creighton University School of Medicine at St Joseph's Hospital and Medical Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Phoenix, AZ, USA.

View Article and Find Full Text PDF
February 2013

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.

Cancer Biol Ther 2012 Sep 16;13(11):1034-41. Epub 2012 Aug 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
September 2012

Ovarian low-grade serous carcinoma: a comprehensive update.

Gynecol Oncol 2012 Aug 30;126(2):279-85. Epub 2012 Apr 30.

Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
August 2012

Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary.

Gynecol Oncol 2012 Jun 14;125(3):515-7. Epub 2012 Mar 14.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston TX 77230-1439, USA.

View Article and Find Full Text PDF
June 2012

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Gynecol Oncol 2012 Jun 6;125(3):661-6. Epub 2012 Mar 6.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA.

View Article and Find Full Text PDF
June 2012

Treatment of ovarian cancer in young women.

Clin Obstet Gynecol 2012 Mar;55(1):65-74

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77230-1439, USA.

View Article and Find Full Text PDF
March 2012

Proceedings from the 9th International Conference on Ovarian Cancer.

Gynecol Oncol 2012 Apr 28;125(1):5-7. Epub 2011 Dec 28.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Find Full Text PDF
April 2012

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Gynecol Oncol 2011 Oct 2;123(1):13-8. Epub 2011 Jul 2.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF
October 2011

Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.

Int J Gynecol Cancer 2011 Jul;21(5):831-6

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35249-7333, USA.

View Article and Find Full Text PDF
July 2011

The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.

Am J Surg Pathol 2011 Jun;35(6):904-12

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article and Find Full Text PDF
June 2011

Low-grade serous primary peritoneal carcinoma.

Gynecol Oncol 2011 Jun 11;121(3):482-6. Epub 2011 Mar 11.

Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77230, USA.

View Article and Find Full Text PDF
June 2011

Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma.

Cancer 2011 Aug 11;117(16):3741-9. Epub 2011 Feb 11.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article and Find Full Text PDF
August 2011

Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Cancer Prev Res (Phila) 2011 Mar 28;4(3):463-70. Epub 2011 Jan 28.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.

View Article and Find Full Text PDF
March 2011

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

Gynecol Oncol 2011 Feb 3;120(2):229-32. Epub 2010 Dec 3.

University of Texas Health Science Center, Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

View Article and Find Full Text PDF
February 2011

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Am J Pathol 2010 Oct 27;177(4):1611-7. Epub 2010 Aug 27.

Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article and Find Full Text PDF
October 2010

Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.

Obstet Gynecol 2010 Aug;116(2 Pt 1):269-273

From the Departments of Gynecologic Oncology, Pathology, and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article and Find Full Text PDF
August 2010